EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
The European Organisation for Research and Treatment of Cancer [...]
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia GalleryTreatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
Brussels, 31 October 2023 - Acute myeloid leukaemia (AML) [...]
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
Important results and the announcement of several new trials [...]
EORTC & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer
The trial is expected to screen more than 1900 [...]
EORTC’s presence at ESMO 2023
New findings and upcoming EORTC trials in lung, head [...]
The EU funded project LEGATO officially started
The European Organisation for Research and Treatment of Cancer [...]
EORTC strategic meeting with Middle Eastern Ambassadors
On 18th of September 2023, EORTC had the honour [...]
Celebrating Sarcoma Awareness Month with the start of EU-funded STREXIT 2 project study
On Sarcoma Awareness Month, the European Organisation for Research [...]
Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma GalleryLong-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma
Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma
The treatment of patients with early stages of Hodgkin [...]
Joint Statement: health organisations define EHDS’ opt out required for life saving research
On the 6th of June, EORTC joined together with [...]
